Seagen (NASDAQ:SGEN – Get Rating) and Advanced Life Sciences (OTCMKTS:ADLS – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.
Profitability
This table compares Seagen and Advanced Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Seagen | -31.10% | -21.13% | -16.79% |
| Advanced Life Sciences | N/A | N/A | N/A |
Analyst Recommendations
This is a summary of recent recommendations for Seagen and Advanced Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Seagen | 0 | 11 | 6 | 0 | 2.35 |
| Advanced Life Sciences | 0 | 0 | 0 | 0 | N/A |
Valuation & Earnings
This table compares Seagen and Advanced Life Sciences’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Seagen | $1.96 billion | 19.56 | -$610.31 million | ($3.30) | -62.29 |
| Advanced Life Sciences | N/A | N/A | N/A | N/A | N/A |
Advanced Life Sciences has lower revenue, but higher earnings than Seagen.
Institutional and Insider Ownership
86.3% of Seagen shares are held by institutional investors. 27.3% of Seagen shares are held by insiders. Comparatively, 12.0% of Advanced Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Seagen beats Advanced Life Sciences on 5 of the 8 factors compared between the two stocks.
About Seagen
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
About Advanced Life Sciences
Advanced Life Sciences Inc. is a biopharmaceutical company and its lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of life-threatening infections including community-acquired bacterial pneumonia and biodefense pathogens including anthrax, plague and tularemia. The Company has developed a promising pipeline of clinical and preclinical product candidates from both in-licensing efforts and the discovery programs in the areas of infectious disease, oncology, and respiratory disease. It develops ALS-357, a natural product in preclinical studies has demonstrated specific anti-tumor activity against malignant melanoma. It has a unique mechanism of action that disrupts mitochondrial membrane function and is associated with the intrinsic, mitochondria-mediated pathway of apoptosis. The Company develops ALS-886, a novel treatment intended to reduce and prevent the tissue damage associated with diseases such as Adult Respiratory Distress Syndrome (ARDS).
Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.
